drugset
drugset / Trial / NCT02106767

The Effects of Rifampin on the Pharmacokinetics of Rosuvastatin

NCT02106767 ↗

Phase 1 Completed 16 enrolled University of California, San Francisco
RandomizedCrossoverOpen-labelOther

Summary

The effect of transporter inhibition by rifampin on the pharmacokinetics of rosuvastatin will be studied in clinical trial in White and Asian healthy volunteers.

Timeline

Start
2014-11
Primary completion
2016-08-07
Completion
2016-08-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifampicin Small molecule 600 mg Intravenous
Subject Rosuvastatin Small molecule 20 mg Oral

Indications

No indication recorded.